These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 28518145)
1. Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer. Xiao L; Lan X; Shi X; Zhao K; Wang D; Wang X; Li F; Huang H; Liu J Cell Death Dis; 2017 May; 8(5):e2803. PubMed ID: 28518145 [TBL] [Abstract][Full Text] [Related]
2. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway. Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534 [TBL] [Abstract][Full Text] [Related]
4. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer. Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500 [TBL] [Abstract][Full Text] [Related]
5. Anesthetic propofol enhances cisplatin-sensitivity of non-small cell lung cancer cells through N6-methyladenosine-dependently regulating the miR-486-5p/RAP1-NF-κB axis. Ling Q; Wu S; Liao X; Liu C; Chen Y BMC Cancer; 2022 Jul; 22(1):765. PubMed ID: 35836137 [TBL] [Abstract][Full Text] [Related]
6. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling. Huang RS; Zheng YL; Zhao J; Chun X Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202 [TBL] [Abstract][Full Text] [Related]
7. CNPY2 enhances resistance to apoptosis induced by cisplatin via activation of NF-κB pathway in human non-small cell lung cancer. Yu D; Qin Y; Jun-Qiang L; Shun-Lin G Biomed Pharmacother; 2018 Jul; 103():1658-1663. PubMed ID: 29864955 [TBL] [Abstract][Full Text] [Related]
8. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner. Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681 [TBL] [Abstract][Full Text] [Related]
9. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations. Gao J; Meng Q; Zhao Y; Chen X; Cai L BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790 [TBL] [Abstract][Full Text] [Related]
10. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways. Zhu B; Ren C; Du K; Zhu H; Ai Y; Kang F; Luo Y; Liu W; Wang L; Xu Y; Jiang X; Zhang Y Biochem Pharmacol; 2019 Dec; 170():113642. PubMed ID: 31541631 [TBL] [Abstract][Full Text] [Related]
11. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005 [TBL] [Abstract][Full Text] [Related]
12. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells. He Y; Xie H; Yu P; Jiang S; Wei L Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523 [TBL] [Abstract][Full Text] [Related]
13. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer. Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838 [TBL] [Abstract][Full Text] [Related]
14. Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small cell lung cancer to cisplatin. Yang Z; Fang S; Di Y; Ying W; Tan Y; Gu W PLoS One; 2015; 10(3):e0121547. PubMed ID: 25799148 [TBL] [Abstract][Full Text] [Related]
15. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770 [TBL] [Abstract][Full Text] [Related]
16. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer. Lin TC; Tsai LH; Chou MC; Chen CY; Lee H Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells. Gao Y; Liu Z; Zhang X; He J; Pan Y; Hao F; Xie L; Li Q; Qiu X; Wang E Cancer Lett; 2013 Aug; 336(1):231-9. PubMed ID: 23673211 [TBL] [Abstract][Full Text] [Related]
18. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867 [TBL] [Abstract][Full Text] [Related]
19. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549]. Li W; Liu X; Zhang G; Zhang L Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536 [TBL] [Abstract][Full Text] [Related]
20. MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway. Li Y; Zu L; Wu H; Zhang F; Fan Y; Pan H; Du X; Guo F; Zhou Q Thorac Cancer; 2022 Feb; 13(3):430-441. PubMed ID: 34953057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]